From leadership changes to groundbreaking diagnostic tools, the company continues to enhance the health and well-being of pets, people, and livestock IDEXX Laboratories, a global leader in veterinary healthcare, has…

From leadership changes to groundbreaking diagnostic tools, the company continues to enhance the health and well-being of pets, people, and livestock

IDEXX Laboratories, a global leader in veterinary healthcare, has unveiled significant updates reflecting its commitment to innovation and excellence. From leadership changes to groundbreaking diagnostic tools, the company continues to enhance the health and well-being of pets, people, and livestock.

Leadership Transition Brian McKeon, Executive Vice President, Chief Financial Officer, and Treasurer, will retire from IDEXX on June 1, 2025. Andrew Emerson, currently Senior Vice President of Corporate and Companion Animal Group (CAG) Finance, will succeed McKeon effective March 1, 2025. To ensure a seamless transition, McKeon will remain as Executive Vice President and Special Advisor until his retirement.

Corporate Responsibility Report IDEXX recently published its 2023 Corporate Responsibility Report, titled Enhancing the Health and Well-being of Pets, People, and Livestock for 40 Years. The report highlights the company’s progress toward achieving its corporate responsibility goals and emphasises its commitment to advancing veterinary medicine through innovative diagnostic insights and software solutions.

Innovative Product Launches

• Catalyst Pancreatic Lipase Test: Launched in June, this single-slide solution enables faster diagnosis of pancreatitis in canine and feline patients. Available in the U.S. and Canada starting in September, the test will roll out globally to over 70,000 Catalyst analyzers in Q4 2024.
• Vello Software Solution: Unveiled in February, Vello facilitates seamless communication between veterinary practices and pet owners using IDEXX practice management software. The service will launch in the U.S. in March 2024 and in Canada in Q2 2024, supporting better health outcomes through informed pet owner engagement.
• IDEXX in Vue Dx Cellular Analyzer: Introduced in January, this slide-free cellular analyzer delivers reference-laboratory quality results in 10 minutes. The analyser uses AI models trained by IDEXX pathologists to provide multidimensional insights for ear and blood sample diagnostics.
• Faecal Dx Antigen Testing Platform Expansion: IDEXX expanded its testing platform to include Cystoisospora, a common intestinal parasite in young dogs and cats. The updated platform will launch in North America in March 2024 and globally in Q3 2024, offering earlier and highly accurate detection of key intestinal parasites.

These advancements reinforce IDEXX Laboratories’ role as a pioneer in veterinary medicine, providing innovative solutions that support healthier, longer lives for pets and their caregivers.